Does using HTK solution for cold perfusion of cadaveric kidneys save money? [1]

Transplantation

Volumn 81, Issue 12, 2006, Pages 1750-

  Englesbe, Michael J ^a   Heidt, David ^a   Sung, Randall ^a   Pietroski, Richard ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Gift of Life Michigan   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HTK SOLUTION; UNIVERSITY OF WISCONSIN SOLUTION;

CADAVER DONOR; COST BENEFIT ANALYSIS; KIDNEY ALLOGRAFT; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LETTER; ORGAN PRESERVATION; PRIORITY JOURNAL;

CADAVER; COLD; HISTIDINE; HUMANS; KETOGLUTARIC ACIDS; KIDNEY; ORGAN PRESERVATION; PERFUSION; SOLUTIONS; TISSUE DONORS; TRYPTOPHAN;

EID: 33745470649     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000226079.94635.3f     Document Type: Letter

References (3)

1. Agarwal A, Goggins WC, Pescovitz MD, et al. Comparison of histidine-tryptophan ketoglutarate and university of Wisconsin solutions as primary preservation in renal allografts undergoing pulsatile perfusion. Transplant Proc 2005; 37(5): 2016.
2. Fridell JA, Agarwal A, Milgrom ML, et al. Comparison of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution for organ preservation in clinical pancreas transplantation. Transplantation 2004; 77(8): 1304.
3. Pokorny H, Rasoul-Rockenschaub S, Langer F, et al. Histidine-tryptophan- ketoglutarate solution for organ preservation in human liver transplantation - a prospective multicentre observation study. Transpl Int 2004; 17(5): 256.